130 related articles for article (PubMed ID: 7510783)
1. Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease.
Gabriel SM; Bierer LM; Davidson M; Purohit DP; Perl DP; Harotunian V
J Neurochem; 1994 Apr; 62(4):1516-23. PubMed ID: 7510783
[TBL] [Abstract][Full Text] [Related]
2. Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex.
Beal MF; Clevens RA; Chattha GK; MacGarvey UM; Mazurek MF; Gabriel SM
J Neurochem; 1988 Dec; 51(6):1935-41. PubMed ID: 2460590
[TBL] [Abstract][Full Text] [Related]
3. Galanin-like immunoreactivity is present in human substantia innominata and in senile plaques in Alzheimer's disease.
Kowall NW; Beal MF
Neurosci Lett; 1989 Mar; 98(1):118-23. PubMed ID: 2469045
[TBL] [Abstract][Full Text] [Related]
4. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease.
Beal MF; Mazurek MF; Svendsen CN; Bird ED; Martin JB
Ann Neurol; 1986 Oct; 20(4):489-95. PubMed ID: 3789664
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease.
Beal MF; Mazurek MF; Chattha GK; Svendsen CN; Bird ED; Martin JB
Ann Neurol; 1986 Sep; 20(3):282-8. PubMed ID: 3767313
[TBL] [Abstract][Full Text] [Related]
6. Galanin-like immunoreactivity within Ch2 neurons in the vertical limb of the diagonal band of Broca in aging and Alzheimer's disease.
Vogels OJ; Renkawek K; Broere CA; ter Laak HJ; van Workum F
Acta Neuropathol; 1989; 78(1):90-5. PubMed ID: 2472041
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease.
Candy JM; Gascoigne AD; Biggins JA; Smith AI; Perry RH; Perry EK; McDermott JR; Edwardson JA
J Neurol Sci; 1985 Dec; 71(2-3):315-23. PubMed ID: 2868073
[TBL] [Abstract][Full Text] [Related]
8. Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease.
Baker-Nigh A; Vahedi S; Davis EG; Weintraub S; Bigio EH; Klein WL; Geula C
Brain; 2015 Jun; 138(Pt 6):1722-37. PubMed ID: 25732182
[TBL] [Abstract][Full Text] [Related]
9. Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases.
Whitford C; Candy J; Edwardson J; Perry R
J Neurol Sci; 1988 Aug; 86(1):13-8. PubMed ID: 2902199
[TBL] [Abstract][Full Text] [Related]
10. Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease.
Beal MF; MacGarvey U; Swartz KJ
Ann Neurol; 1990 Aug; 28(2):157-61. PubMed ID: 1699471
[TBL] [Abstract][Full Text] [Related]
11. A disorganized increase of galanin-like immunoreactivity in cerebral cortex of Alzheimer-type dementia brains.
Minami M; Makino Y; Arai H; Iizuka R
J Neural Transm Park Dis Dement Sect; 1991; 3(4):285-92. PubMed ID: 1722980
[TBL] [Abstract][Full Text] [Related]
12. Degeneration of the basalocortical pathway from the cortex induces a functional increase in galaninergic markers in the nucleus basalis magnocellularis of the rat.
Barbelivien A; Vaussy C; Marchalant Y; Maubert E; Bertrand N; Beley A; Roussel S; Mackenzie ET; Dauphin F
J Cereb Blood Flow Metab; 2004 Nov; 24(11):1255-66. PubMed ID: 15545921
[TBL] [Abstract][Full Text] [Related]
13. Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex.
Gabriel SM; Bierer LM; Harotunian V; Purohit DP; Perl DP; Davis KL
Neurosci Lett; 1993 May; 155(1):116-20. PubMed ID: 8103205
[TBL] [Abstract][Full Text] [Related]
14. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease.
Beal MF; Mazurek MF; Tran VT; Chattha G; Bird ED; Martin JB
Science; 1985 Jul; 229(4710):289-91. PubMed ID: 2861661
[TBL] [Abstract][Full Text] [Related]
15. Characterization of galanin-like immunoreactivity in the rat brain: effects of neonatal glutamate treatment.
Gabriel SM; MacGarvey UM; Koenig JI; Swartz KJ; Martin JB; Beal MF
Neurosci Lett; 1988 Apr; 87(1-2):114-21. PubMed ID: 2454423
[TBL] [Abstract][Full Text] [Related]
16. Galanin immunoreactivity in human CSF: studies in eating disorders and Alzheimer's disease.
Berrettini WH; Kaye WH; Sunderland T; May C; Gwirtsman HE; Mellow A; Albright A
Neuropsychobiology; 1988; 19(2):64-8. PubMed ID: 2465504
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin-28(1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex.
Beal MF; Benoit R; Mazurek MF; Bird ED; Martin JB
Brain Res; 1986 Mar; 368(2):380-3. PubMed ID: 2870772
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes.
Beal MF; Mazurek MF; Martin JB
Brain Res; 1986 Nov; 397(2):386-8. PubMed ID: 3801878
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex.
Gabriel SM; Davidson M; Haroutunian V; Powchik P; Bierer LM; Purohit DP; Perl DP; Davis KL
Biol Psychiatry; 1996 Jan; 39(2):82-91. PubMed ID: 8717605
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex.
Perry RH; Dockray GJ; Dimaline R; Perry EK; Blessed G; Tomlinson BE
J Neurol Sci; 1981 Sep; 51(3):465-72. PubMed ID: 6268760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
